ORIGINAL ARTICLE

In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus

Zhong Li, Jimin Xu, Yuekun Lang, Xiangmeng Wu, Saiyang Hu, Subodh Kumar Samrat, Anil M. Tharapel, Lili Kuo, David Butler, Yongcheng Song, Qing-Yu Zhang, Jia Zhou, Hongmin Li

Department of Pharmacology and Toxicology, College of Pharmacy, Tucson, AZ 85721-0207, USA
Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA
Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA
The Neural Stem Cell Institute, Rensselaer, NY 12144, USA
Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030, USA

Received 23 August 2021; received in revised form 30 September 2021; accepted 4 October 2021

KEY WORDS
Flavivirus;
Zika virus;
Dengue virus;
Antiviral;
Protease inhibitor;
Erythrosin B

Abstract
Zika virus (ZIKV) causes significant human diseases without specific therapy. Previously we found erythrosin B, an FDA-approved food additive, inhibited viral NS2B–NS3 interactions, leading to inhibition of ZIKV infection in cell culture. In this study, we performed pharmacokinetic and in vivo studies to demonstrate the efficacy of erythrosin B against ZIKV in 3D mini-brain organoid and mouse models. Our results showed that erythrosin B is very effective in abolishing ZIKV replication in the 3D organoid model. Although pharmacokinetics studies indicated that erythrosin B had a low absorption profile, mice challenged by a lethal dose of ZIKV showed a significantly improved survival rate upon oral administration of erythrosin B, compared to vehicle control. Limited structure–activity relationship studies indicated that most analogs of erythrosin B with modifications on the xanthene ring led to loss or reduction of inhibitory activities towards viral NS2B–NS3 interactions, protease activity and antiviral efficacy. In contrast, introducing chlorine substitutions on the isobenzofuran ring led to slightly increased

Abbreviations: aa, amino acid; AUC, area under the curve; DENV, dengue virus; DMSO, dimethyl sulfoxide; dpi, day post infection; EB, erythrosin B; FDA, US Food and Drug Administration; FRET, fluorescence resonance energy transfer; ip, intraperitoneal; NS, non-structural protein; ORF, open reading frame; PFU, plaque-forming unit; PK, pharmacokinetic; PP, polyprotein precursor; SAR, structure–activity relationship; SLC, split luciferase complementation; UTR, untranslated region; WHO, World Health Organization; ZIKV, Zika virus.

*Corresponding author. Tel.: +1 520 621 5728.
E-mail address: bli1@pharmacy.arizona.edu (Hongmin Li).
†These authors made equal contributions to this work.
Peer review under responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences

https://doi.org/10.1016/j.apsb.2021.10.017
2211-3835 © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
activities, suggesting that the isobenzofuran ring is well tolerated for modifications. Cytotoxicity studies indicated that all derivatives are nontoxic to human cells. Overall, our studies demonstrated erythrosin B is an effective antiviral against ZIKV both in vitro and in vivo.

© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Zika virus (ZIKV) is a member of the genus Flavivirus. ZIKV and many other flaviviruses such as dengue virus (DENV) are significant human pathogens. ZIKV outbreaks have occurred worldwide, leading to devastating diseases, including central nervous system malformations such as Guillain-Barré syndrome, microcephaly and congenital Zika syndrome. DENVs cause life-threatening diseases such as dengue shock syndrome and dengue hemorrhagic fever, now together termed as severe dengue by WHO. DENV infection threatens 3.9 billion people, leading to 22,000 deaths per year worldwide. A DENV vaccine was recently approved in a few countries. However, it is not effective for young children, and may pose an increased risk for naive children. Although there are effective vaccines for a few flaviviruses, safe and effective vaccines for many flaviviruses including ZIKV have not been developed or approved by US Food and Drug Administration (FDA).

The flaviviral genome is composed of 5′-untranslated region (UTR), a single open reading frame (ORF), and 3′-UTR. A polyprotein precursor (PP) encoded by the ORF will be co- and post-translationally processed by viral and cellular proteases into individual functional proteins. NS3 is a multi-functional viral protein with activities of a serine protease, an RNA triphosphatase, a nucleoside triphosphatase, and a helicase. The viral NS3 protease is located at the N-terminal 184 amino acids (aa) of viral NS3 protein and requires a hydrophobic core of about 40 aa in length within viral NS2B protein as an essential cofactor. NS3 protease complex is required for NS3 function. In recent studies, we identified several clinically-used and FDA-approved compounds as inhibitors against viral NS2B–NS3 protease complex, including erythrosin B (EB), an FDA-approved food additive. EB functions as an inhibitor to abolish the essential binding of co-factor NS2B to the viral protease NS3. Docking and mutagenesis studies confirmed that EB bound in a pocket formed by residues Y23, I25, Q28, F46, and L58 of the DENV3 NS3 protease. It is noted that except Q28 which is neither conserved nor essential, all other 4 residues are highly conserved and essential for binding of EB to NS3. Consistently, in vitro, EB was found as a broad-spectrum inhibitor against multiple flaviviruses with an appreciable therapeutic window. EB was also found to inhibit virus replication in multiple cell types including lung carcinoma cells, human placental epithelial cells, and human neural progenitor and stem cells.

In this study, we explored the in vivo antiviral efficacy of EB using 3D organoid and mouse models. We found that EB significantly reduced ZIKV infection on a 3D-mini forebrain organoid model derived from pluripotent neural stem cells. The survival rate of mice infected by a lethal dose of ZIKV was significantly improved by EB treatment, compared to that by vehicle control. To improve the potency and reduce potential side effects, we performed a limited scale of structure–activity relationship (SAR) study. We found that modification of I on the xanthene ring led to the loss of antiviral activity, whereas introducing chlorine substitutions on the isobenzofuran ring maintained the same level of potency in inhibition of NS2B–NS3 interaction, protease activity, and antiviral efficacy, indicating that the isobenzofuran ring is tolerated for modifications.

2. Results and discussion

2.1. Chemistry

The general synthetic routes of erythrosin B and its derivatives were summarized in Scheme 1. Coupling of substituted resorcinols 1a–d with various phthalic anhydrides 2a–e afforded fluorescein derivatives 4–9. Indolation of 4 and 9 produced derivatives 10 and 11, respectively. Bromination of 4 with NBS (4.0 or 2.5 eq) gave tetrabromo- and dibromo-derivatives 12 and 13, respectively. Further nitration of 13 yielded compound 14. Commercially available iso thiocyanate 15 was coupled with trityl-protected cysteamine to give the intermediate, which was then converted into the final product 17 via acidic deprotection. The detailed synthetic procedures of these derivatives followed the reported protocols in literatures. The structures and purities of all synthesized compounds were evaluated by 1H and 13C NMR and HPLC analysis, respectively. All compounds are >95% pure.

2.2. Erythrosin B protects 3D mini-forebrain organoid from ZIKV infection

Previously, we found that EB inhibited ZIKV infection in neural progenitor and placenta cells relevant to ZIKV pathogenesis using 2D cell culture. Here we further investigated whether EB could protect against ZIKV-associated neurological damage using a 3D mini-forebrain organoid model, as we described previously.

Following published protocol, we generated the 3D mini-forebrain organoid from induced pluripotent stem cells. We first evaluated if EB could damage the 3D organoid. Our results showed that EB treatment did not lead to any changes in morphology of the 3D organoids (Fig. 1A, upper panel), suggesting that EB at 3.0 μmol/L is not toxic to the organoid. In contrast, temoporfin, an inhibitor blocking NS2B–NS3 interactions we identified previously, showed significant toxicity to the 3D organoids (Supporting Information Fig. S2), even though it only showed moderate cellular cytotoxicity. As shown, upon temoporfin treatment, the organoids fell apart and lost clear organoid boundary, indicating toxicity. Next, we used a full-length
infectious ZIKV clone expressing Venus fluorescent protein (ZIKV-Venus) to evaluate the antiviral efficacy of EB in the organoid model. Our results showed that organoids treated with DMSO showed significant fluorescence, indicating successful ZIKV infection (Fig. 1A, lower panel, and Fig. S2). In contrast, EB-treated organoids showed greatly reduced fluorescence [Fig. 1A (lower panel) and B, and Fig. S2], suggesting less viral infection and replication. Our results suggest that ZIKV infection in the 3D organoid is significantly reduced by EB treatment.

We next used immunostaining to evaluate viral antigen expression in the 3D organoid. Using the 4G2 antibody which recognizes flaviviral envelope protein, we showed that DMSO-treated organoid is fully susceptible to ZIKV infection, showing viral antigen expression throughout the organoid (Fig. 1B). In contrast, only very limited viral antigen expression was found for EB-treated organoids.

We next quantified virus production using plaque-forming unit assay. Our results showed that EB treatment reduced ZIKV production by the 3D organoids up to 2-log order, compared to the DMSO control. Collectively, our results demonstrate that EB treatment can prevent ZIKV infection in human cortical tissue.

2.3. Pharmacokinetic (PK) analysis of EB

To study the PK properties, EB was first administered to female B6 mice at 50 mg/kg by intraperitoneal (ip) injection (Fig. 2A, Table 1). EB was absorbed rapidly in mice and reached the plasma peak concentration in 15 min. The clearance of EB is relatively slower with a t1/2 about 2 h. To examine the oral bioavailability of EB, the compound was administered to female B6 mice at 100 mg/kg by oral gavage (Fig. 2B). Compared to that with ip administration, the absorption of EB was also very rapid. It reached the plasma peak concentration in about 20 min. The clearance is also relatively slow with t1/2 of about 3 h. However, the Cmax and AUC were both much lower in the oral administrated group than those in the ip one, indicating that EB has relatively low absorption via the oral route.

2.4. In vivo antiviral efficacy

We next performed an in vivo antiviral efficacy study using an IfnR−/−/C0−/C0 ZIKV mouse model as we described previously. Because we observed differences in susceptibility to ZIKV challenge between male and female mice, we evaluated male and female mice separately. Our results showed that male mice are more susceptible to ZIKV challenge than females. 1.7 × 10⁵ PFU ZIKV PRVABC59 led to 100% moribundity of male mice. In contrast, 1.7 × 10⁴ PFU ZIKV only resulted in a 75% moribundity of female mice (Fig. 3). Compared to the vehicle control group with 100% lethality, male mice treated with 200 mg/kg EB daily for 7 days survived 75% (Fig. 3A). Increasing dosage to 400 mg/kg did not further improve the survival rate (Fig. 3B). For female mice,
Removing I at R3 position (JMX0903) or replacing I with Br at R1 positions (JMX0892, JMX0897) also abolished the inhibitory activity against the NS2B/C0 (IC50-SLC > 15 μM/L, which is consistent with their low protease inhibitory activity. In contrast, our data showed that JMX0902 was slightly more potent than EB in inhibition of Zika virus replication, with an EC50 of 0.3 μM/L (Fig. 4C), which is in agreement with its better inhibitory activity to the NS2B–NS3 protease than that of EB.

Finally, we measured the cell cytotoxicity of these compounds towards A549 cells. Our data showed that all derivatives are well tolerated by A549 cells, with CC50 > 200 μM/L (Fig. 4D).

3. Conclusions

Flaviviruses represent significant human pathogens. During the last two decades, frequent outbreaks of flaviviruses such as West Nile virus, DENV, and most recently ZIKV, occurred worldwide. Unfortunately, no specific therapy exists to treat flavivirus infections. A recent study shows that orthosteric and allosteric inhibitors against viral NS2B–NS3 protease provide a promise for therapeutic development.17,35–37

Previously, we identified EB as a potent inhibitor abolishing flavivirus NS2B–NS3 interactions, resulting in inhibition of the viral protease activity and viral replication in 2D cell culture.17,37. In this study, we investigated the antiviral efficacy of EB using 3D organoid and in vivo mouse models. We showed that the food dye EB can effectively impair the viral replication activity36. In this study, we investigated the antiviral efficacy of EB using 3D organoid and in vivo mouse models. We showed that the food dye EB can effectively impair the viral replication activity.
replication in a 3D mini-brain organoid model and greatly improved the survival rate of mice challenged by a lethal dose of Zika virus. Our SAR studies indicated that iodine substitutions at R1 and R3 positions of the xanthene ring are essential for EB’s biological activities, and chlorine substitutions are allowed on the isobenzofuran ring of EB. Overall, our results showed that EB is the most effective compound among those analogs to combat Zika infections.

4. Experimental

4.1. Compounds

4.1.1. General chemistry information

Materials and solvents in reagent grade were purchased from commercial vendors and directly used without further purification. The reference erythrosin B was also procured from Sigma–Aldrich. All reactions were performed in dry glassware with magnetic stirring under a nitrogen atmosphere. The Silica gel 60 with a particle size of 0.063 mm (70–230 mesh, flash) was used for preparative column chromatography. The F254 plates with Silica gel 60 (Merck, Darmstadt) were used for analytical thin layer chromatography. UV (254 nm) was used to visualize the developed chromatograms. A Brucker-300 (1H NMR, 300 MHz; 13C NMR, 75 MHz) spectrometer was used to record NMR spectra. TMS was used as an internal reference to record 1H and 13C NMR spectra, with chemical shifts in ppm and values in Hz. A Shimadzu analytical HPLC system (model: CBM-20A LC-20AD SPD-20A UV/Vis) was used to determine purities of final compounds, as we described previously.

4.1.1.1. 3’,6’-Dihydroxy-3H-spiro[isobenzofuran-1,9’-xanthene]-3-one (4, JMX0915) Red solid. HPLC purity 95.5% ($t_R = 14.72$ min). 1H NMR (300 MHz, DMSO-d6) $\delta$ 10.09 (s, 2H), 7.99 (d, $J = 7.5$, 1H), 7.79 (td, $J = 7.5$, 1.3 Hz, 1H), 7.71 (td, $J = 7.5$, 1.1 Hz, 1H), 7.26 (d, $J = 7.6$ Hz, 1H), 6.68 (t, $J = 1.4$ Hz, 2H), 6.55 (d, $J = 1.4$ Hz, 4H). 13C NMR (75 MHz, DMSO-d6) $\delta$ 168.7, 159.5, 152.4, 151.9, 135.5, 130.0, 129.0, 126.2, 124.6, 124.0, 112.6, 109.6, 102.2.

4.1.1.2. 4’,5’-Dichloro-3’,6’-dihydroxy-3H-spiro[isobenzofuran-1,9’-xanthene]-3-one (5, JMX0892). Yellow solid. HPLC purity 98.0% ($t_R = 14.59$ min). 1H NMR (300 MHz, CD3OD) $\delta$ 8.03–7.96 (m, 1H), 7.77 (td, $J = 7.5$, 1.3 Hz, 1H), 7.69 (td, $J = 7.4$, 1.1 Hz, 1H), 7.24–7.16 (m, 1H), 6.68 (d, $J = 2.2$ Hz, 2H), 6.61–6.48 (m, 4H). 13C NMR (75 MHz, CD3OD) $\delta$ 171.6, 161.3, 154.1, 136.5, 131.0, 130.1, 128.3, 125.8, 125.4, 113.6, 111.4, 103.6.

4.1.1.3. 2’,7’-Dichloro-3’,6’-dihydroxy-3H-spiro[isobenzofuran-1,9’-xanthene]-3-one (6, JMX0897). Orange solid. HPLC purity 99.2% ($t_R = 16.48$ min). 1H NMR (300 MHz, DMSO-d6) $\delta$ 11.08 (s, 2H), 8.01 (d, $J = 7.4$ Hz, 1H), 7.82 (t, $J = 7.4$ Hz, 1H), 7.74 (t, $J = 7.3$ Hz, 1H), 7.33 (d, $J = 7.5$ Hz, 1H), 6.91 (s, 2H), 6.65 (s, 2H). 13C NMR (75 MHz, DMSO-d6) $\delta$ 168.3, 155.2, 151.5, 150.1, 135.9, 130.5, 128.2, 125.9, 125.1, 124.0, 116.3, 110.5, 103.8.

4.1.1.4. Sodium 4’,5’-diido-3-oxo-3H-spiro[isobenzofuran-1,9’-xanthene]-3’,6’-bis(olate) (7, JMX0903). Red solid. HPLC purity 95.0% ($t_R = 16.68$ min). 1H NMR (300 MHz, DMSO-d6) $\delta$ 8.10–8.01 (m, 1H), 7.53–7.39 (m, 2H), 7.12–7.03 (m, 1H), 6.58 (d, $J = 9.3$ Hz, 2H), 6.16 (d, $J = 9.3$ Hz, 2H). 13C NMR (75 MHz, DMSO-d6) $\delta$ 176.2, 169.6, 157.3, 155.4, 140.6, 133.7, 130.1, 129.8, 128.8, 128.1, 127.9, 120.2, 110.0, 79.3.

4.1.1.5. 3’,6’-Dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9’-xanthene]-5-carboxylic acid (8, JMX0920). Yellow solid. HPLC purity 99.1% ($t_R = 13.52$ min). 1H NMR (300 MHz, DMSO-d6) $\delta$ 13.53 (s, 1H), 10.17 (s, 2H), 8.40 (s, 1H), 8.29 (dd, $J = 8.0$, 1.5 Hz, 1H), 7.39 (d, $J = 8.0$, 1.0 Hz, 1H), 6.70 (d, $J = 2.2$ Hz, 2H), 6.61 (d, $J = 8.6$ Hz, 2H), 6.55 (dd, $J = 8.7$, 2.3 Hz, 2H). 13C NMR (75 MHz, DMSO-d6) $\delta$ 167.8, 166.0, 159.7, 156.1, 151.8, 136.1, 132.9, 129.2, 126.8, 125.5, 124.6, 112.7, 108.9, 102.3.

4.1.1.6 Sodium 4,5,6,7-tetrachloro-2’,4’,5’,7’-tetraiodo-3-oxo-3H-spiro[isobenzofuran-1,9’-xanthene]-3’,6’-bis(olate) (II, JMX0902). Dark red solid. HPLC purity 95.1% ($t_R = 21.08$ min).
Figure 3  In vivo antiviral activity of EB against ZIKV. (A) and (B) Survival percentage for four-week-old A129 male mice infected with ZIKV PRVABC59 (1.7 × 10^5 PFU) and treated with EB 200 mg/kg (n = 12) (A) or EB 400 mg/kg (n = 4) (B) or vehicle (n = 9) via oral gavage. (C) Survival percentage of female mice infected with ZIKV (1.7 × 10^5 PFU) and treated with EB 200 mg/kg (n = 15) or vehicle (n = 15). All survival curves were compared using the Log-rank test. ****P < 0.0001; **P < 0.005; *P < 0.05.

13C NMR (75 MHz, DMSO-d6) δ 171.6, 164.4, 157.3, 145.4, 143.4, 136.9, 132.6, 128.3, 127.7, 127.2, 110.7, 96.4, 75.3.

4.1.1.7. 2',4',5',7'-tetabromo-3',6'-diidroxy-3H-spiro[isobenzofuran-1',9'-xanthen]-3-one (12, JMX0911). Dark red solid. HPLC purity 95.6% (tR = 12.78 min). 1H NMR (300 MHz, CD3OD) δ 8.04–8.79 (m, 1H), 7.77 (td, J = 7.4, 1.4 Hz, 1H), 7.69 (td, J = 7.4, 1.1 Hz, 1H), 7.27–7.21 (m, 1H), 6.69 (d, J = 8.8 Hz, 2H), 6.59 (d, J = 8.8 Hz, 2H). 13C NMR (75 MHz, CD3OD) δ 171.0, 158.5, 150.8, 147.2, 141.2, 129.7, 129.0, 126.6, 124.1, 117.1, 113.2, 112.67, 110.9, 102.3, 46.9, 22.8.

4.1.1.8. 4',5',6'-dibromo-3',6'-diidroxy-3H-spiro[isobenzofuran-1',9'-xanthen]-3-one (13, JMX0983). Yellow solid. HPLC purity 99.3% (tR = 16.37 min). 1H NMR (300 MHz, CD3OD) δ 8.04–7.97 (m, 1H), 7.77 (td, J = 7.4, 1.4 Hz, 1H), 7.69 (td, J = 7.4, 1.1 Hz, 1H), 7.27–7.21 (m, 1H), 6.69 (d, J = 8.8 Hz, 2H), 6.59 (d, J = 8.8 Hz, 2H). 13C NMR (75 MHz, CD3OD) δ 171.0, 158.5, 150.8, 136.7, 131.3, 128.3, 128.0, 126.1, 125.4, 113.6, 112.7, 99.4.

4.1.1.9. 4',5',6'-dibromo-3',6'-diidroxy-2',7'-dinitro-3H-spiro[isobenzofuran-1',9'-xanthen]-3-one (14, JMX0910). Yellow solid. HPLC purity 97.0% (tR = 18.44 min). 1H NMR (300 MHz, CD3OD) δ 8.07 (d, J = 7.4 Hz, 1H), 7.19 (d, J = 7.4 Hz, 1H), 7.14 (s, 2H). 13C NMR (75 MHz, CD3OD) δ 168.3, 164.3, 153.3, 137.6, 134.4, 130.9, 129.9, 127.9, 127.3, 125.7, 105.4.

4.1.1.10 1-(3',6'-Dihydroxy-3-oxo-3H-spiro[isobenzofuran-1',9'-xanthen]-5')-3-(2-mercaptopethyl)thiourea (17, JMX0912). Yellow solid. HPLC purity 95.0% (tR = 14.88 min). 1H NMR (300 MHz, CD3OD) δ 10.05 (s, 1H), 8.83 (s, 2H), 8.29–8.20 (m, 2H), 7.75 (d, J = 8.2 Hz, 1H), 7.19 (d, J = 8.3 Hz, 1H), 6.68 (d, J = 2.2 Hz, 2H), 6.64–6.54 (m, 4H), 3.68 (q, J = 6.5 Hz, 2H), 2.73 (q, J = 7.4 Hz, 2H), 2.45 (t, J = 8.1 Hz, 1H). 13C NMR (75 MHz, DMSO-d6) δ 180.6, 168.5, 159.6, 158.6, 158.1, 152.0, 147.2, 141.2, 129.7, 129.0, 126.6, 124.1, 117.1, 113.2, 112.67, 109.8, 102.3, 46.9, 22.8.

4.2. Split luciferase complementation (SLC) assay

The SLC assay was performed using purified proteins as previously described36,39,46. All experiments described here and below were performed in triplicate, unless specified. The software suite GraphPad Prism 9.0 (GraphPad Software, San Diego, CA, USA) was used to fit dose-dependent titration points using non-linear regression function to determine all inhibitory IC50/EC50/CC50 values.

4.3. Protease inhibition assay

Protease inhibition assay was carried out with the His-tagged NS2B (50 nmol/L), DENV2 NS3-MBP fusion protein (50 nmol/L), and a FRET substrate Abz-RRRRSAG-nTyr (NeoScientific, Cambridge, MA, USA) as we described previously17,35–37.

4.4. Cytotoxicity assay

A WST-8 cell proliferation assay (Enzo Life Science, Farmingdale, NY, USA) was used to determine cytotoxicity for EB and derivatives, as described previously17,35–37,47,48.

4.5. Plaque forming unit (PFU) assays

The effect of erythrosin B on ZIKV PRVABC59 was determined by a PFU viral plaque reduction assay using A549 cells [American Type Culture Collection (ATCC), Manassa, VA, USA] as described previously17,35–37,47,48. No mycoplasma contamination was detected in all cells.

4.6. Culture of 3D mini-brain organoid

Generation of the 3D mini-brain organoid mimicking forebrain was cultured as described previously35,37.

4.7. Immunofluorescence assay

The 3D mini-brain organoids at Day 20 were treated with DMSO or erythrosin B (3.0 μmol/L) as described previously35,37. At Day 21, the organoids were treated with DMSO or EB (3.0 μmol/L) and infected with ZIKV PRVABC59 at MOI of 1 or mock. MOI was estimated by estimation of cell numbers based on organoid volume. At 5 days post infection (dpi), ZIKV titer in culture supernatant was evaluated by the PFU assay. At 7 dpi, the 3D organoids were fixed and sectioned for immunohistochemistry staining, as described previously35,37. An Olympus DP71 fluorescence imaging system was used to record fluorescence images. Quantification of relative
fluorescence unit (RFU) was done using the ImageJ suite. Quantification of virus yield was carried out using the PFU assay as described above. Student t-test was used to calculate statistical significance.

4.8. Pharmacokinetics of EB

C57BL/6 (B6) mice (female, 20–22 g) were obtained from breeding stocks maintained at the University of Arizona. All mice were housed under conditions of controlled temperature (22 °C) with on-off light cycle, with food and water provided ad libitum. EB was given to mice by intraperitoneal injection (ip) at 50 mg/kg (in 50% PEG containing 10% ethanol and 10% DMSO) or by oral gavage at 100 mg/kg (in 10% Solutol HS 15 containing 10% DMSO). The University of Arizona Animal Care and Use Committee approved all animal studies.

Heparinized capillary tubes were used to collect blood samples through the tail vein at various time as indicated in the figure legends after dosing. Plasma was prepared and stored at −30 °C until analysis. Plasma sample (5 μL) was mixed with 30 μL methanol and 10 μL of internal standard (IS; cholic acid-d₄ 1 μg/mL), then diluted with 760 μL water before loaded onto an ISOLUTE C₁₈ SPE Columns (1 mL/100 mg, Biotage, Salem, NH, USA). After washed with 1 mL water, the analytes were eluted from the cartridges with 1 mL methanol, dried with nitrogen, and reconstituted in 100 μL methanol prior to LC−MS/MS analysis.

LC−MS/MS was used to detect EB. The LC−MS system is composed of a Sciex Qtrap6500 Mass Spectrometer (AB SCIEX, Framingham, MA, USA) and an Agilent 1290 UPLC system (Agilent Technologies, Santa Clara, CA, USA). An ACQUITY C₁₈ column (2.1 mm × 100 mm, 1.7 μm, Waters) was used to separate analytes at temperature of 35 °C, with mobile phase A containing 10 mmol/L ammonium acetate in water and mobile phase B containing 10 mmol/L ammonium acetate in acetonitrile. Elution was programed as follows: 10% B (0–0.5 min), 10% B→90% B (0.5–0.6 min), 90% B (0.6–3 min), 90% B→10% B (3–3.1 min), 10% B (3.1–5.5 min), with a flow rate of 0.2 mL/min. The MS was operated in the negative ion mode, using electrospray ionization. The ion spray temperature and voltage were set at 500 °C and 4500 V, respectively. Ion source gas 1, 2 and curtain gas were set at 25, 25, 20 psi, respectively. EB and the internal standard (IS, cholic acid-d₄) were detected using Multiple Reaction Monitoring (MRM), with a dwell time of 150 msec per transition, at mz 834.5/
Zika virus inhibitor

662.8 and 411.0/411.0, respectively. For quantitative analysis of erythrosine B, standards (5–1000 ng/mL in 10 μL methanol), along with 10 μL IS (at 1 μg/mL in methanol), were added to 5 μL of blank mouse plasma to construct the calibration curve.

PK solver (Microsoft, Redmond, WA, USA) was used to calculate the pharmacokinetic parameters by assuming a non-compartamental model.

4.9. In vivo protection efficacy

As we described previously17, a ZIKV survival animal model was used to evaluate the in vivo antiviral activity of EB, which was approved by the Wadsworth Center IACUC and Institutional Biosafety Committees.

1.7 × 10^4 or 1.7 × 10^5 PFU of the PRVABC59 strain was administered to a group of four-week-old A129 male (M) and female (F) mice by subcutaneous injection, respectively. Then, the infected mice were treated with EB at 200 mg/kg \( n = 12 \) (M); \( n = 15 \) (F) or 400 mg/kg \( n = 4 \) (M) of body weight or with vehicle control \( n = 9 \) (M), or \( n = 15 \) (F) every day through oral gavage for 7 consecutive days post-infection (dpi). Mice were examined daily for signs of illness and mortality for 14 days. The Log-rank test was used to compare survival curves.

Acknowledgments

This study was partially supported by grants AI131669, AI140726, and AI140491, USA, and by the R. Ken and Donna Coit Endowed Chair Fund at UTMB. Hongmin Li is additionally supported by NIH grants AI133219, AI134568, AI140406, and AI140491, USA, and by the R. Ken and Donna Coit Endowed Chair fund in Drug Discovery.

Author contributions

Zhong Li, Jimin Xu, David Butler, Yongcheng Song, Qing-Yu Zhang, Jia Zhou and Hongmin Li conceived the concept of the study. Zhong Li, Jimin Xu, Yuekun Lang, Xiangmeng Wu, Saiyang Hu, Subodh Kumar Samrat, and Anil M. Tharappel performed the experiments. Zhong Li, Jimin Xu, Xiangmeng Wu, Yongcheng Song, Qing-Yu Zhang, Jia Zhou and Hongmin Li wrote the manuscript.

Conflicts of interest

The authors declare that they have no potential conflicts of interest involving the contents of this article.

Appendix A. Supporting information

Supporting information to this article can be found online at https://doi.org/10.1016/j.apsb.2021.10.017.

References

1. Brecher M, Zhang J, Li H. The flavivirus protease as a target for drug discovery. Virol Sin 2013;28:326–36.
2. Calvet G, Aguiar RS, Melo AS, Sampaio SA, de Filippis I, Fabri A, et al. Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. Lancet Infect Dis 2016;16:653–60.
3. Thomas DL, Sharp TM, Torres J, Armstrong PA, Munoz-Jordan J, Ryff KR, et al. Local transmission of Zika virus—Puerto Rico, November 23, 2015—January 28, 2016. MMWR Morb Mortal Wkly Rep 2016;65:154–8.
4. Martines RB, Bhatnagar J, Keating MK, Silva-Flannery L, Muelhlenbachs A, Gary J, et al. Notes from the field: evidence of Zika virus infection in brain and placental tissues from two congenitally infected newborns and two fetal losses—Brazil, 2015. MMWR Morb Mortal Wkly Rep 2016;65:159–60.
5. Rodriguez-Morales AJ. Zika and microcephaly in Latin America: an emerging threat for pregnant travelers?. Trav Med Infect Dis 2016;14:5–6.
6. Li C, Xu D, Ye Q, Hong S, Jiang Y, Liu X, et al. Zika virus disrupts neural progenitor development and leads to microcephaly in mice. Cell Stem Cell 2016;19:120–6.
7. WHO. Dengue and severe dengue. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.
8. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term safety of a Dengue vaccine in regions of endemic disease. N Engl J Med 2015;373:1195–206.
9. Aguiau M, Stollenwerk N, Halstead SB. The impact of the newly licensed Dengue vaccine in endemic countries. PLoS Neglected Trop Dis 2016;10:e0005179.
10. Ferguson NM, Rodriguez-Barracaqu I, Dorigatti I, Mier YT-RL, Laydon DJ, Cummings DA. Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment. Science 2016;353:1033–6.
11. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990;44:649–88.
12. Warrener P, Tamura JK, Collett MS. RNA-stimulated NTPase activity associated with yellow fever virus NS3 protein expressed in bacteria. J Virol 1993;67:989–96.
13. Wengler G. The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology 1991;184:707–15.
14. Bartelma G, Padmanabhan R. Expression, purification, and characterization of the RNA 5'-triphosphatase activity of dengue virus type 2 nonstructural protein 3. Virology 2002;299:122.
15. Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim S, et al. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 2006;13:372–3.
16. Brecher M, Li Z, Liu B, Zhang J, Koetzner CA, Alifarag A, et al. A conformational switch high-throughput screening assay and allosteric inhibition of the flavivirus NS2B–NS3 protease. PLoS Pathog 2017;13:e1006411.
17. Li Z, Brecher M, Zhang J, Sakamura S, Liu B, Huang R, et al. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B–NS3 interaction. Cell Res 2017;27:1046–64.
18. Prussis P, Lapins M, Yahorava S, Petrovska R, Niyomrattanakit P, Katzenmeier G, et al. Proteochromometric analysis of substrate interactions with dengue virus NS3 proteases. Bioorg Med Chem 2008;16:9369–77.
19. Chambers TJ, Grakoui A, Rice CM. Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J Virol 1991;65:6042–50.
20. Falgout B, Pethel M, Zhang YM, Lai CJ. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol 1991;65:2467–75.
21. Luo D, Xu T, Sampath A, Lim SP, Canard B, et al. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target. Antivir Res 2008;80:94—101.

22. Noble CG, Seh CC, Chao AT, Shi PY. Ligand-bound structures of the dengue virus protease reveal the active conformation. J Virol 2012;86:438—46.

23. Aleshin A, Shiryaev S, Strongin A, Liddington R. Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci 2007;16:795—806.

24. Assenberg R, Mastrangelo E, Walter TS, Verma A, Milani M, Owens RJ, et al. Crystal structure of the NS3 protease-helicase from dengue virus. J Virol 2009;83:12895—906.

25. Chandramouli S, Joseph JS, Daudenarde S, Gatchalian J, Cornillez-Ty C, Kuhn P. Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. J Virol 2010;84:3059—67.

26. Hammamy MZ, Haase C, Hammami M, Hilgenfeld R, Steinmetzer T. Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B—NS3 protease. ChemMedChem 2013;8:231—41.

27. Luo D, Wei N, Doan DN, Paradkar PN, Chong Y, Davidson AD, et al. Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications. J Biol Chem 2010;285:18817—27.

28. Luo D, Xu T, Hunke C, Grüber G, Vasudevan SG, Lescar J. Crystal structure of the NS3 protease-helicase from dengue virus. J Virol 2008;82:173—83.

29. Luo D, Xu T, Watson RP, Scherer-Becker D, Sampath A, Jahnke W, et al. Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. EMBO J 2008;27:3209—19.

30. Robin G, Chappell K, Stoeerner MJ, Hu SH, Young PR, Fairlie DP, et al. Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J Mol Biol 2009;385:1568—77.

31. Lei J, Hansen G, Nitsche C, Klein CD, Zhang L, Hilgenfeld R. Crystal structure of Zika virus NS2B—NS3 protease in complex with a boronate inhibitor. Science 2016;353:503—5.

32. Zhang Z, Li Y, Loh YR, Phoo WW, Hung AW, Kang C, et al. Crystal structure of unlinked NS2B—NS3 protease from Zika virus. Science 2016;354:1597—600.

33. Phoo WW, Li Y, Zhang Z, Lee MY, Loh YR, Tan YB, et al. Structure of the NS2B—NS3 protease from Zika virus after self-cleavage. Nat Commun 2016;7:13410.

34. Kang C, Keller TH, Luo D. Zika virus protease: an antiviral drug target. Trends Microbiol 2017;25:797—808.

35. Li Z, Lang Y, Sakamuru S, Samrat S, Trudeau N, Kuo L, et al. Methylene blue is a potent and broad-spectrum inhibitor against Zika virus in vitro and in vivo. Emerg Microbes Infect 2020;9:2404—16.

36. Li Z, Sakamuru S, Huang R, Brecher M, Koetzner CA, Zhang J, et al. Erythrosin B is a potent and broad-spectrum orthosteric inhibitor of the flavivirus NS2B—NS3 protease. Antivir Res 2018;150:217—25.

37. Li Z, Xu J, Lang Y, Fan X, Kuo L, D’Brant L, et al. JMX0207, a niclosamide derivative with improved pharmacokinetics, suppresses Zika virus infection both in vitro and in vivo. ACS Infect Dis 2020;6:2616—28.

38. Li Z, Zhang J, Li H. Flavivirus NS2B/NS3 Protease: structure, function, and inhibition. In: Gupta SP, editor, editors. Viral proteases and their inhibitors. San Diego, CA: Elsevier; 2017. p. 163—88.

39. Lang Y, Li Z, Li H. Analysis of protein—protein interactions by split luciferase complementation assay. Curr Protoc Toxicol 2019;82:e90.

40. Yao Y, Huo T, Lin YL, Nie S, Wu F, Hua Y, et al. Discovery, X-ray crystallography and antiviral activity of allosteric inhibitors of Flavivirus NS2B—NS3 protease. J Am Chem Soc 2019;141:6832—6.

41. Rudra JS, Ding Y, Neelakantan H, Ding C, Appavu R, Stutz S, et al. Suppression of cocaine-evoked hyperactivity by self-adjuvanting and multivalent peptide nanofiber vaccines. ACS Chem Neurosci 2016;7:546—52.

42. Benkovics G, Afonso D, Darcsi A, Beni S, Conoci S, Fenyesi E, et al. Novel beta-cyclodextrin-eosin conjugates. Beilstein J Org Chem 2017;13:543—51.

43. Pomorski A, Adamczyk J, Bishop AC, Krezel A. Probing the target-specific inhibition of sensitized protein tyrosine phosphatases with biarsenical probes. Org Biomol Chem 2015;13:1395—403.

44. Pietranconsta N, Kessler A, Favre-Besse FC, Triballeau N, Quentin T, Giros B, et al. Rose bengal analogs and vesicular glutamate transporters (VGLUTs). Bioorg Med Chem 2010;18:6922—33.

45. Park S, Foote PK, Krist DT, Rice SE, Statsyuk A, VGLUTs: novel probes for ring-between-ring (RBR) E3 ubiquitin ligase PARKIN. J Biol Chem 2017;292:16539—53.

46. Li Z, Brecher M, Zhang J, Sakamuru S, Liu B, Huang R, et al. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B—NS3 interaction. Cell Res 2017;27:1046—64.

47. Chen H, Liu L, Jones SA, Banavali N, Kass J, Li Z, et al. Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs. Antivir Res 2013;97:232—9.

48. Chen H, Zhou B, Brecher M, Banavali N, Jones SA, Li Z, et al. S-Adenosyl-homocysteine is a weakly bound inhibitor for a flaviviral methyltransferase. PLoS One 2013;8:e76900.

49. Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671—5.